ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Treatment strategy for newly diagnosed Hodgkin lymphoma: current evidence].

Interim positron emission tomography (PET) -guided therapy and brentuximab vedotin (BV) combined systemic chemotherapy have been developed for newly diagnosed classical Hodgkin's lymphoma (cHL). A majority of recent trials using interim PET response-adapted approaches have assessed the treatment strategies for cHL and reported that the initial treatment could be suitably altered to intensive treatment in an early phase, thereby enhancing the efficacy in interim PET-positive patients, whereas the simplified treatment regimen, such as omitting drugs or radiation, could minimize the risk of toxicity in interim PET-negative patients. This review includes the current evidence primarily focusing on randomized clinical trials including patients with newly diagnosed cHL to investigate the efficacy and safety of interim PET-guided therapy or BV combined regimen and also mentions that issues.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app